<DOC>
	<DOCNO>NCT00199069</DOCNO>
	<brief_summary>The study evaluate efficacy tolerability risk- subtype-adapted chemotherapy one year , follow randomize either intensified conventional maintenance therapy . It include distinct protocol subgroup 'mature B-ALL ' ,</brief_summary>
	<brief_title>German Multicenter Trial Treatment Newly Diagnosed Acute Lymphoblastic Leukemia Adults ( 05/93 )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Acute Lymphocytic Leukemia Age 15 65 year Serious secondary disease may compromise intensified chemotherapeutical treatment Serious psychiatric disease , may compromise compliance therapy HIV1 HIV2 Infection Pretreatment &gt; 2 week chemotherapy Vincristine Steroids Patients without central diagnosis allocate risk group</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>ALL</keyword>
	<keyword>Treatment</keyword>
	<keyword>De Novo</keyword>
	<keyword>Adult</keyword>
</DOC>